AVTX
Avalo Therapeutics, Inc.
$14.76
+7.97%
$775.9M
No data for this timeframe.
Vol
Market Cap$775.9M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (95%)
Inst. Holders40 funds
Inst. Value$205.9M
Inst. Activity10 buys / 4 sells
Insider Activity0B / 14S
Insider Net $-$2.5M
SEC Reports8
Press Releases3
Recent Activity
Jun 10, 2026
Insider
Sullivan Christopher Ryan surrendered for taxes 138 shares
Chief Financial Officer @ $13.10 ($1.8K)
Jun 10, 2026
Insider
VARKI PAUL surrendered for taxes 1,081 shares
Chief Legal Officer @ $13.10 ($14.2K)
Jun 10, 2026
Insider
Riley Jennifer surrendered for taxes 588 shares
Chief Strategy Officer @ $13.10 ($7.7K)
Jun 10, 2026
short_volume
Short Volume: AVTX — 69.6% short (0.5M / 0.7M)
Short: 512,095 | Exempt: 12 | TRF Vol: 735,938 | Short Ratio: 69.6% | Off-exchange volume (dark pool
Jun 8, 2026
SEC
Avalo Therapeutics filed an 8-K reporting that stockholders approved the Second Amended and Restated 2016 Employee Stock
8-K — Impact 3/10
May 13, 2026
SEC
Avalo Therapeutics reported Q1 2026 EPS of -$0.98, missing the -$1.01 consensus by 3.0% (a miss), with no revenue. The h
PRESS-RELEASE — Impact 8/10
May 13, 2026
SEC
Avalo Therapeutics reported Q1 2026 results with a narrower-than-expected EPS loss of -$0.98 (vs consensus -$1.00) and h
8-K — Impact 8/10
Inst.
FMR LLC — DOUBLED
2,879,481 shares ($43.0M)
Price Targets
$45.25
+206.6% upside
Strong Buy
Current $14.76
Low $34.00
Median $43.50
High $60.00
12 analysts
$34.00
$60.00
Analyst Ratings
8Strong Buy
10Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 12, 2026 | B of A Securities | INITIATE | Buy |
| May 14, 2026 | Citizens | MAINTAIN | Market Outperform → Market Outperform |
| May 14, 2026 | Wedbush | MAINTAIN | Outperform → Outperform |
| May 14, 2026 | Mizuho | MAINTAIN | Outperform → Outperform |
| May 14, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.62 ▲ +30.1% | $-0.94 — $-0.46 | 68% YoY | 9 |
| Next Q | $-0.56 ▲ +21.4% | $-0.84 — $-0.27 | 74% YoY | 9 |
| Current FY | $-2.62 ▲ +16.6% | $-3.53 — $-1.77 | 55% YoY | 10 |
| Next FY | $-2.80 ▲ +15.7% | $-4.10 — $-1.33 | -7% YoY | 10 |
Latest Reports
NEUTRAL
8-K
3/10
Avalo Therapeutics filed an 8-K reporting that stockholders approved the Second Amended and Restated 2016 Employee Stock
Jun 8, 2026
BULLISH
PRESS-RELEASE
8/10
Avalo Therapeutics reported Q1 2026 EPS of -$0.98, missing the -$1.01 consensus by 3.0% (a miss), with no revenue. The h
May 13, 2026
BEARISH
Press
7/10
Avalo Therapeutics priced a $375M underwritten public offering of 19.73M shares at $17.75/share plus pre-funded warrants
May 6, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| FMR LLC | $43.0M | DOUBLED |
| Avoro Capital Advisors LLC | $21.1M | NEW |
| Point72 Asset Management, L.P. | $13.7M | ADD |
| FARALLON CAPITAL MANAGEMENT LLC | $13.7M | NEW |
| RTW INVESTMENTS, LP | $12.8M | NEW |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 10, 2026 | Sullivan Christopher | F | $1.8K |
| Jun 10, 2026 | VARKI PAUL | F | $14.2K |
| Jun 10, 2026 | Riley Jennifer | F | $7.7K |
| Jun 10, 2026 | Doyle Mittie | F | $14.2K |
| Jun 2, 2026 | Truex Samantha | A | $0.00 |
40 institutional holders with $205.9M total value (13,836,271 shares) as of 2026-Q1. Top holders: FMR, Avoro, Point72. Net buying activity: 10 institutions added/increased vs 4 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | FMR LLC | 2,879,481 | $43.0M | 20.9% | DOUBLED +1207.1% |
| 2 | Avoro Capital Advisors LLC | 1,410,000 | $21.1M | 10.2% | NEW |
| 3 | Point72 Asset Management, L.P. | 916,142 | $13.7M | 6.6% | ADD +46.0% |
| 4 | FARALLON CAPITAL MANAGEMENT LLC | 916,000 | $13.7M | 6.6% | NEW |
| 5 | RTW INVESTMENTS, LP | 856,962 | $12.8M | 6.2% | NEW |
| 6 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 854,000 | $12.8M | 6.2% | ADD +55.3% |
| 7 | BALYASNY ASSET MANAGEMENT L.P. | 731,586 | $10.9M | 5.3% | ADD +66.5% |
| 8 | VANGUARD CAPITAL MANAGEMENT LLC | 719,694 | $10.7M | 5.2% | — |
| 9 | RA CAPITAL MANAGEMENT, L.P. | 662,968 | $9.9M | 4.8% | TRIM -28.9% |
| 10 | BANK OF AMERICA CORP /DE/ | 643,000 | $9.6M | 4.7% | ADD +49.0% |
| 11 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 474,200 | $7.1M | 3.4% | — |
| 12 | JENNISON ASSOCIATES LLC | 470,775 | $7.0M | 3.4% | — |
| 13 | BlackRock, Inc. | 327,082 | $4.9M | 2.4% | ADD +87.7% |
| 14 | CITADEL ADVISORS LLC | 193,735 | $2.9M | 1.4% | — |
| 15 | AMERIPRISE FINANCIAL INC | 172,149 | $2.6M | 1.2% | — |
| 16 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 163,000 | $2.4M | 1.2% | — |
| 17 | MORGAN STANLEY | 161,392 | $2.4M | 1.2% | TRIM -39.1% |
| 18 | Hudson Bay Capital Management LP | 161,087 | $2.4M | 1.2% | DOUBLED +860.5% |
| 19 | DEUTSCHE BANK AG\ | 150,000 | $2.2M | 1.1% | — |
| 20 | MARSHALL WACE, LLP | 129,136 | $1.9M | 0.9% | TRIM -74.6% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| FMR LLC | DOUBLED | 220,300 | 2,879,481 | +1207.1% | $43.0M | 2026-Q1 |
| Avoro Capital Advisors LLC | NEW | — | 1,410,000 | — | $21.1M | 2026-Q1 |
| Point72 Asset Management, L.P. | ADD | 627,502 | 916,142 | +46.0% | $13.7M | 2026-Q1 |
| FARALLON CAPITAL MANAGEMENT LLC | NEW | — | 916,000 | — | $13.7M | 2026-Q1 |
| RTW INVESTMENTS, LP | NEW | — | 856,962 | — | $12.8M | 2026-Q1 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | ADD | 550,000 | 854,000 | +55.3% | $12.8M | 2026-Q1 |
| BALYASNY ASSET MANAGEMENT L.P. | ADD | 439,312 | 731,586 | +66.5% | $10.9M | 2026-Q1 |
| MORGAN STANLEY | TRIM | 264,907 | 161,392 | -39.1% | $2.4M | 2026-Q1 |
| Hudson Bay Capital Management LP | DOUBLED | 16,771 | 161,087 | +860.5% | $2.4M | 2026-Q1 |
| MARSHALL WACE, LLP | TRIM | 507,550 | 129,136 | -74.6% | $1.9M | 2026-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 18,300 | 120,114 | +556.4% | $1.8M | 2026-Q1 |
| GLENMEDE TRUST CO NA | ADD | 20,450 | 25,730 | +25.8% | $384.1K | 2026-Q1 |
| ExodusPoint Capital Management, LP | TRIM | 32,267 | 17,751 | -45.0% | $265.0K | 2026-Q1 |
| OMERS ADMINISTRATION Corp | TRIM | 19,600 | 11,800 | -39.8% | $176.2K | 2026-Q1 |
| Point72 Asset Management, L.P. | TRIM | 1,053,983 | 627,502 | -40.5% | $11.4M | 2025-Q4 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | DOUBLED | 258,769 | 550,000 | +112.5% | $10.0M | 2025-Q4 |
| MARSHALL WACE, LLP | DOUBLED | 56,009 | 507,550 | +806.2% | $9.2M | 2025-Q4 |
| BALYASNY ASSET MANAGEMENT L.P. | TRIM | 817,436 | 439,312 | -46.3% | $8.0M | 2025-Q4 |
| BlackRock, Inc. | ADD | 154,251 | 289,571 | +87.7% | $5.3M | 2025-Q4 |
| MORGAN STANLEY | DOUBLED | 10 | 264,907 | +2648970.0% | $4.8M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 49,242 | 148,237 | +201.0% | $2.7M | 2025-Q4 |
| STATE STREET CORP | ADD | 45,454 | 79,254 | +74.4% | $1.4M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | NEAR_EXIT | 98,700 | 18,300 | -81.5% | $332.3K | 2025-Q4 |
| GROUP ONE TRADING LLC | NEAR_EXIT | 281 | 1 | -99.6% | $18.00 | 2025-Q4 |
| Point72 Asset Management, L.P. | NEW | — | 1,053,983 | — | $13.4M | 2025-Q3 |
13 unique insiders with 50 transactions. Net insider value: -$2.5M ($0.00 bought, $2.5M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 10, 2026 | Sullivan Christopher Ryan | Chief Financial Officer | TAX W/H | 138 | $13.10 | $1.8K |
| Jun 10, 2026 | VARKI PAUL | Chief Legal Officer | TAX W/H | 1,081 | $13.10 | $14.2K |
| Jun 10, 2026 | Riley Jennifer | Chief Strategy Officer | TAX W/H | 588 | $13.10 | $7.7K |
| Jun 10, 2026 | Doyle Mittie | Chief Medical Officer | TAX W/H | 1,084 | $13.10 | $14.2K |
| Jun 2, 2026 | Truex Samantha | Director | AWARD | 20,100 | — | — |
| Jun 2, 2026 | KANTOFF AARON | Director | AWARD | 20,100 | — | — |
| Jun 2, 2026 | KAPLAN GILLA | Director | AWARD | 20,100 | — | — |
| Jun 2, 2026 | Lind Kevin Robert | Director | AWARD | 20,100 | — | — |
| Jun 2, 2026 | Jain Rita | Director | AWARD | 20,100 | — | — |
| Jun 2, 2026 | Heffernan Michael Thomas | Director | AWARD | 29,500 | — | — |
| May 28, 2026 | Doyle Mittie | Chief Medical Officer | EXERCISE | 679 | $8.04 | $5.5K |
| May 28, 2026 | Doyle Mittie | Chief Medical Officer | SELL | 679 | $16.00 | $10.9K |
| May 21, 2026 | Riley Jennifer | Chief Strategy Officer | AWARD | 34,200 | — | — |
| May 21, 2026 | NEIL GARRY ARTHUR | Chief Executive Officer | AWARD | 100,200 | — | — |
| May 21, 2026 | VARKI PAUL | Chief Legal Officer | AWARD | 24,300 | — | — |
| May 21, 2026 | Sullivan Christopher Ryan | Chief Financial Officer | AWARD | 39,900 | — | — |
| May 21, 2026 | Doyle Mittie | Chief Medical Officer | AWARD | 43,500 | — | — |
| May 15, 2026 | Doyle Mittie | Chief Medical Officer | EXERCISE | 3,000 | $12.65 | $38.0K |
| May 15, 2026 | Doyle Mittie | Chief Medical Officer | SELL | 3,000 | $18.76 | $56.3K |
| May 7, 2026 | Sullivan Christopher Ryan | Chief Financial Officer | EXERCISE | 18,606 | $9.88 | $183.8K |
| May 7, 2026 | Sullivan Christopher Ryan | Chief Financial Officer | SELL | 18,606 | $24.12 | $448.8K |
| May 6, 2026 | VARKI PAUL | Chief Legal Officer | SELL | 37,375 | $18.91 | $706.8K |
| May 6, 2026 | VARKI PAUL | Chief Legal Officer | EXERCISE | 62,500 | $13.43 | $839.4K |
| May 6, 2026 | Sullivan Christopher Ryan | Chief Financial Officer | SELL | 13,834 | $18.55 | $256.7K |
| May 6, 2026 | Sullivan Christopher Ryan | Chief Financial Officer | EXERCISE | 47,000 | $8.04 | $377.9K |
| May 6, 2026 | Doyle Mittie | Chief Medical Officer | SELL | 27,538 | $18.03 | $496.4K |
| May 6, 2026 | Doyle Mittie | Chief Medical Officer | EXERCISE | 77,905 | $12.65 | $985.5K |
| May 6, 2026 | Chan Mitchell | Director | SELL | 3,167 | $22.88 | $72.5K |
| May 5, 2026 | Doyle Mittie | Chief Medical Officer | SELL | 1,679 | $16.00 | $26.9K |
| May 5, 2026 | Doyle Mittie | Chief Medical Officer | EXERCISE | 1,000 | $12.65 | $12.7K |
| Apr 30, 2026 | Sullivan Christopher Ryan | Chief Financial Officer | SELL | 8,457 | $13.23 | $111.9K |
| Apr 29, 2026 | Sullivan Christopher Ryan | Chief Financial Officer | SELL | 8,458 | $13.09 | $110.7K |
| Apr 6, 2026 | Doyle Mittie | Chief Medical Officer | SELL | 3,970 | $18.01 | $71.5K |
| Apr 6, 2026 | Doyle Mittie | Chief Medical Officer | EXERCISE | 3,970 | $12.65 | $50.2K |
| Apr 2, 2026 | Sullivan Christopher Ryan | Chief Financial Officer | SELL | 6,200 | $17.02 | $105.6K |
| Apr 1, 2026 | Sullivan Christopher Ryan | Chief Financial Officer | SELL | 500 | $15.86 | $7.9K |
| Apr 1, 2026 | Doyle Mittie | Chief Medical Officer | SELL | 679 | $16.00 | $10.9K |
| Apr 1, 2026 | Doyle Mittie | Chief Medical Officer | EXERCISE | 679 | $8.04 | $5.5K |
| Mar 31, 2026 | Lind Kevin Robert | Director | AWARD | 1,370 | $12.13 | $16.6K |
| Mar 31, 2026 | Jain Rita | Director | AWARD | 1,339 | $12.13 | $16.2K |
| Mar 28, 2026 | Chan Mitchell | Director | EXERCISE | 3,166 | — | — |
| Mar 28, 2026 | Goldman Jonathan | Director | EXERCISE | 3,166 | — | — |
| Mar 28, 2026 | NEIL GARRY ARTHUR | Chief Executive Officer | EXERCISE | 64,866 | — | — |
| Mar 28, 2026 | NEIL GARRY ARTHUR | Chief Executive Officer | TAX W/H | 21,892 | $13.89 | $304.1K |
| Mar 28, 2026 | Sullivan Christopher Ryan | Chief Financial Officer | EXERCISE | 24,200 | — | — |
| Mar 28, 2026 | Sullivan Christopher Ryan | Chief Financial Officer | TAX W/H | 8,241 | $13.89 | $114.5K |
| Mar 28, 2026 | KAPLAN GILLA | Director | EXERCISE | 3,166 | — | — |
| Mar 28, 2026 | Truex Samantha | Director | EXERCISE | 3,166 | — | — |
| Mar 28, 2026 | KANTOFF AARON | Director | EXERCISE | 3,166 | — | — |
| Mar 16, 2026 | Doyle Mittie | Chief Medical Officer | EXERCISE | 19,500 | $12.65 | $246.7K |
8 SEC filing reports analyzed. Sentiment: 2 bullish, 1 bearish, 1 mixed, 4 neutral. Avg impact: 5.3/10.
NEUTRAL
8-K
3/10
Avalo Therapeutics filed an 8-K reporting that stockholders approved the Second Amended and Restated
Jun 8, 2026
BULLISH
PRESS-RELEASE
8/10
Avalo Therapeutics reported Q1 2026 EPS of -$0.98, missing the -$1.01 consensus by 3.0% (a miss), wi
May 13, 2026
BULLISH
8-K
8/10
Avalo Therapeutics reported Q1 2026 results with a narrower-than-expected EPS loss of -$0.98 (vs con
May 13, 2026
BEARISH
CLUSTER
6/10
Four Avalo Therapeutics insiders — including the CFO, CLO, and CMO — sold a total of $1.53M in open-
May 11, 2026
MIXED
424B5
6/10
Avalo Therapeutics filed a preliminary prospectus supplement for an underwritten public offering of
May 5, 2026
NEUTRAL
DEFA14A
4/10
Avalo Therapeutics is holding its 2026 Annual Meeting to vote on the election of seven directors, ap
Apr 10, 2026
NEUTRAL
CLUSTER
4/10
Two C-suite executives at Avalo Therapeutics — the CFO and Chief Medical Officer — sold shares worth
Apr 8, 2026
NEUTRAL
CLUSTER
3/10
Two C-suite executives at Avalo Therapeutics — the CFO and CMO — sold a combined $19K in open-market
Apr 3, 2026
BEARISH
7/10
Avalo Therapeutics priced a $375M underwritten public offering of 19.73M shares at $17.75/share plus
May 6, 2026
BULLISH
8/10
Avalo Therapeutics announced positive Phase 2 LOTUS trial results for abdakibart in hidradenitis sup
May 5, 2026
BEARISH
6/10
Avalo Therapeutics reported its 2025 financial results, highlighting a net loss of $78.3 million ami
Mar 23, 2026
Current analyst consensus: Strong Buy (95% buy). Based on 19 analysts: 8 strong buy, 10 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$45.25 mean target
+206.6% upside
Strong Buy (1.14)
$34.00 Low
$60.00 High
| Metric | Value |
|---|---|
| Current Price | $14.76 |
| Target Low | $34.00 |
| Target Mean | $45.25 |
| Target Median | $43.50 |
| Target High | $60.00 |
| # Analysts | 12 |
| Recommendation | Strong Buy (1.14) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.62 | $-0.94 | $-0.46 | 67.8% | +30.1% | 0↑ 1↓ | $0.0B | 0.0% | 9 |
| Next Q 2026-09-30 |
$-0.56 | $-0.84 | $-0.27 | 74.3% | +21.4% | 1↑ 0↓ | $0.0B | 0.0% | 9 |
| Current FY 2026-12-31 |
$-2.62 | $-3.53 | $-1.77 | 55.1% | +16.6% | 2↑ 0↓ | $0.0B | -100.0% | 10 |
| Next FY 2027-12-31 |
$-2.80 | $-4.10 | $-1.33 | -6.8% | +15.7% | 1↑ 1↓ | $0.0B | 0.0% | 10 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.618 | |
| 7d ago | $-0.627 | +0.010 |
| 30d ago | $-0.883 | +0.266 |
| 60d ago | $-0.952 | +0.334 |
| 90d ago | $-1.583 | +0.965 |
9 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 5 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 12, 2026 | B of A Securities | INITIATE | — | Buy |
| May 14, 2026 | Citizens | MAINTAIN | Market Outperform | Market Outperform |
| May 14, 2026 | Wedbush | MAINTAIN | Outperform | Outperform |
| May 14, 2026 | Mizuho | MAINTAIN | Outperform | Outperform |
| May 14, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| May 11, 2026 | Piper Sandler | MAINTAIN | Overweight | Overweight |
| May 6, 2026 | Citizens | MAINTAIN | Market Outperform | Market Outperform |
| May 6, 2026 | Wedbush | MAINTAIN | Outperform | Outperform |
| May 6, 2026 | BTIG | MAINTAIN | Buy | Buy |
| Apr 13, 2026 | BTIG | REITERATE | Buy | Buy |
| Apr 9, 2026 | Wolfe Research | INITIATE | — | Outperform |
| Apr 6, 2026 | Citizens | INITIATE | — | Market Outperform |
| Mar 25, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Mar 24, 2026 | BTIG | REITERATE | Buy | Buy |
| Feb 2, 2026 | Guggenheim | INITIATE | — | Buy |
| Jan 15, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Dec 18, 2025 | Mizuho | INITIATE | — | Outperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 8 | 10 | 1 | 0 | 0 | 95% | |
| May 1, 2026 | 7 | 10 | 1 | 0 | 0 | 94% | |
| Apr 1, 2026 | 7 | 9 | 1 | 0 | 0 | 94% | |
| Mar 1, 2026 | 7 | 9 | 1 | 0 | 0 | 94% | |
| Feb 1, 2026 | 6 | 9 | 1 | 0 | 0 | 94% | |
| Jan 1, 2026 | 6 | 9 | 1 | 0 | 0 | 94% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 10, 2026
short_volume
Short Volume: AVTX — 69.6% short (0.5M / 0.7M)
Short: 512,095 | Exempt: 12 | TRF Vol: 735,938 | Short Ratio: 69.6% | Off-exchange volume (dark pool + OTC)
Jun 9, 2026
short_volume
Short Volume: AVTX — 70.1% short (0.4M / 0.6M)
Short: 416,845 | Exempt: 0 | TRF Vol: 594,653 | Short Ratio: 70.1% | Off-exchange volume (dark pool + OTC)
May 22, 2026
other
Avalo Therapeutics Announces Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
<p align="justify">WAYNE, PA., May 22, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company full
May 21, 2026
Clinical Trial
A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppurativa
Phase Phase 2 — COMPLETED
May 21, 2026
clinical_trial_readout
Results Pending: AVTX-009 Regimen 1 (Phase 2) — Completed 87d ago
Trial: A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppurativa
Sponsor: Avalo Therapeutic
May 13, 2026
earnings
Avalo Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates
<p align="justify">WAYNE, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) (“Avalo”), a clinical stage biotechnology co
May 11, 2026
earnings_calendar
AVTX Q1 2026 Earnings Scheduled — 2026-05-11
May 6, 2026
offering
Avalo Therapeutics Announces Pricing of $375 Million Public Offering
<p>WAYNE, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ: AVTX) (“Avalo”), a clinical-stage biotechnology company fully dedi
May 5, 2026
offering
Avalo Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
<p align="justify">WAYNE, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ: AVTX) (“Avalo”), a clinical-stage biotechnology co
May 5, 2026
fda
Avalo Therapeutics Achieves Positive Topline Results in Phase 2 LOTUS Trial of Abdakibart (AVTX-009) in Moderate to Severe Hidradenitis Suppurativa
<p align="justify">WAYNE, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company full
May 5, 2026
short_interest
FTD: AVTX — 44,761 shares ($0.6M) failed to deliver
Settlement: 20260505, Price: $13.78, FTD Value: $616,806.58, AVALO THERAPEUTICS INC COM PAR
May 4, 2026
short_interest
FTD: AVTX — 54,048 shares ($0.7M) failed to deliver
Settlement: 20260504, Price: $13.71, FTD Value: $740,998.08, AVALO THERAPEUTICS INC COM PAR
Apr 21, 2026
clinical_trial_readout
Results Pending: AVTX-009 Regimen 1 (Phase 2) — Completed 57d ago
Trial: A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppurativa
Sponsor: Avalo Therapeutic
Mar 24, 2026
short_volume
Short Volume: AVTX — 66.8% short (0.3M / 0.5M)
Short: 348,956 | Exempt: 0 | TRF Vol: 522,429 | Short Ratio: 66.8% | Off-exchange volume (dark pool + OTC)
Mar 23, 2026
earnings
Avalo Therapeutics Reports 2025 Financial Results and Recent Business Updates
<p align="justify">WAYNE, Pa., March 23, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) (“Avalo”), a clinical stage biotechnology
Mar 18, 2026
earnings_calendar
AVTX Q4 2025 Earnings After Market Close — 2026-03-18